Category Archives: On-Sale Bar

Federal Circuit reverses DC grant of SJ based on § 102(b) on-sale bar defense (e.g., inventor declarations not “sham affidavits”)

Quest Integrity USA, LLC v. Cokebusters USA Inc. Docket No. 2017-2423 DYK, TARANTO, HUGHES May 21, 2019 Brief summary: DC grant of SJ based on § 102(b) on-sale bar defense (e.g., inventor declarations not “sham affidavits”) reversed. Summary: Quest appealed … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar, Prosecution History Estoppel | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 (FC panel); June 25, 2018 (SCOTUS); Jan. 24, 2019 (SCOTUS) Update 2 (Jan. 24, 2019): Update 2 (Jan. 24, 2019): SCOTUS affirmed the FC panel decision, holding that “a commercial … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

SCOTUS Docket No. 17-1229 FC Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 Brief Summary: In its May decision, an FC panel reversed the DC and found the asserted claims invalid under the § 102(b) on-sale bar, the … Continue reading

Posted in On-Sale Bar | Leave a comment

The Medicines Company v. Hospira, Inc.

Docket No. 2014-1469, -1504 DYK, WALLACH, HUGHES February 6, 2018 Brief summary: DC’s decision that distribution agreement was not an offer for sale reversed as the agreement “make[s] clear that [MedCo] and ICS entered into an agreement to sell and … Continue reading

Posted in Claim Construction, Infringement, On-Sale Bar | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 Brief Summary: FC panel reversed DC and found the asserted claims invalid under the § 102(b) on-sale bar. The FC panel concluded that the AIA did not change the meaning … Continue reading

Posted in America Invents Act, Anticipation (35 USC 102), Generics / ANDA, On-Sale Bar | Leave a comment

The Medicines Company (“MedCo”) v. Hospira, Inc.

Docket No. 2014-1469, -1504 En banc opinion July 11, 2016 Brief Summary: En banc opinion concluded “a product produced pursuant to the claims of a product-by-process patent is ‘on sale’ under 35 U.S.C. § 102(b)…must be the subject of a … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar | Leave a comment

Merck & CIE et al. v. Watson Laboratories, Inc.

Docket No. 2015-2063, -2064 DYK, MAYER, HUGHES May 13, 2016 Brief Summary: DC decision that there was no § 102(b) on-sale bar reversed due to fax including “all the required elements to qualify as a commercial offer for sale” (“essential … Continue reading

Posted in On-Sale Bar | Leave a comment